Gathering the record
Relay is organizing the evidence and source boundaries.
Long-acting human amylin analogue
An experimental weight-loss drug designed to help people feel full after eating.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Two peer-reviewed randomized Phase 1 trials plus the 493-participant ZUPREME-1 Phase 2 obesity trial reported by the sponsor.
The estimated half-life was about 10 days and the largest 16-week mean loss was 8.6%.
Mean reduction reached 10.7% in the best-performing arm versus 1.7% placebo.
Women reportedly lost more weight than men in ZUPREME-1.
Ongoing trials do not establish benefit.
Its appetite and weight biology comes through amylin-receptor signaling.
Risks & unknowns
Relay has not verified a clear pattern of side effects for this compound.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryInvestigational — Phase 2 obesity evidence Full Phase 2 publication, sex-related response differences, longer-term maintenance, combination performance, Phase 3 outcomes, and rare-event safety.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
Adults with overweight or obesity entered separate 6-week or 16-week multiple-dose cohorts.
| Cohort | Starting amount | Target / pattern |
|---|---|---|
| 6-week cohorts | 0.6 or 1.2 mg | No escalation |
| 16-week cohort 1 | 0.6 mg | 2.4 mg target |
| 16-week cohort 2 | 0.6 mg | 4.8 mg target |
| 16-week cohort 3 | 1 mg | 9 mg target |
The 16-week cohorts used planned increases every 2 weeks. Intermediate steps are not reconstructed here. These separate cohorts are not one recommended progression.
Petrelintide · randomized Phase 1b trial Full text · Multiple ascending-dose study, parts 1–2This reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Peer-reviewed early research evaluated petrelintide in adults with overweight or obesity to measure safety, exposure, and short-term weight change.
Population: Adults with overweight or obesity
Design: Two randomized, placebo-controlled multiple-dose trials
Mechanisms
Petrelintide is a long-acting analogue of human amylin. Two randomized Phase 1 studies reported an approximately 10-day half-life and weight reduction up to 8.6% after 16 weeks, with mostly mild gastrointestinal adverse events. In the 493-participant ZUPREME-1 Phase 2 trial, Roche reported mean weight reduction up to 10.7% at 42 weeks versus 1.7% with placebo. The sponsor highlighted a low vomiting rate and no gastrointestinal discontinuations in the maximally effective arm, but a sex difference in weight response and the absence of a peer-reviewed Phase 2 paper remain important uncertainties. Diabetes and combination studies are ongoing.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Two Phase 1 trials, Phase 2 obesity, and ongoing metabolic studies.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The largest result remains sponsor-reported.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The randomized cohorts were small and followed participants for only 6 or 16 weeks. Early study material does not establish long-term outcomes, an approved regimen, or preparation rules for independent vials. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Two randomized, placebo-controlled multiple-dose trials
Adults with overweight or obesity
Petrelintide had an approximately 10-day half-life and produced mean weight reduction up to 8.6% at 16 weeks.
Study administration: Once-weekly subcutaneous petrelintide or placebo
Limitations: Small early-phase cohorts cannot define long-term efficacy or uncommon harms.
Randomized study in type 2 diabetes
Adults with type 2 diabetes and overweight or obesity
ZUPREME-2 is evaluating metabolic effects in type 2 diabetes.
Study administration: Weekly petrelintide or comparator
Limitations: No completed results were available.
Randomized, double-blind, placebo-controlled dose-ranging trial
Adults with overweight or obesity
The sponsor reported mean weight reduction up to 10.7% versus 1.7% with placebo.
Study administration: Five weekly petrelintide dose regimens or placebo
Limitations: Full peer-reviewed Phase 2 methods and results were not available at cutoff.
Official registry record for ZUPREME-1
Adults with overweight or obesity
The registry confirms the randomized Phase 2 design and population.
Study administration: Weekly petrelintide or placebo
Limitations: The registry does not independently establish the reported effect size.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-04-01 · PMID 42017294 · DOI 10.1111/dom.70753
2026-03-05
2025-04-01 · NCT06926842
2024-11-01 · NCT06662539